These pharma stocks are likely to benefit from the Semaglutide launch, as per analysts

Generic versions have been introduced at steep discounts, with monthly therapy costs ranging from about ₹1,290 to ₹8,000, compared to ₹8,800 to ₹16,400 for the innovator drug.

Leave a Reply

Your email address will not be published. Required fields are marked *